Get the Stockscreener App
44.69
0.90%
0.40
Pre-market:
44.33
-0.36
-0.81%
Xenon Pharmaceuticals Inc stock is traded at $44.69, with a volume of 459.67K.
It is up +0.90% in the last 24 hours and up +14.33% over the past month.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
See More
Previous Close:
$44.29
Open:
$44.29
24h Volume:
459.67K
Relative Volume:
0.59
Market Cap:
$3.45B
Revenue:
$13.17M
Net Income/Loss:
$-199.06M
P/E Ratio:
-16.31
EPS:
-2.74
Net Cash Flow:
$-156.53M
1W Performance:
+0.45%
1M Performance:
+14.33%
6M Performance:
+46.72%
1Y Performance:
+5.55%
1-Day Range:
$43.25
$44.75
1-Week Range:
$42.35
$44.81
52-Week Range:
$26.74
$45.01
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
(604) 484-3300
Address
200 - 3650 GILMORE WAY, BURNABY
Compare XENE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
44.69 | 3.42B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jan-04-24 | Initiated | Citigroup | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-14-22 | Initiated | Goldman | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Oct-19-22 | Initiated | Raymond James | Outperform |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Jul-21-22 | Initiated | JP Morgan | Overweight |
| Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Jul-21-20 | Initiated | Needham | Buy |
| Jun-01-20 | Resumed | Jefferies | Buy |
| Mar-25-20 | Initiated | Wedbush | Outperform |
| Jan-08-20 | Initiated | William Blair | Outperform |
| Sep-20-19 | Initiated | Guggenheim | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Mar-13-17 | Initiated | Jefferies | Buy |
| Oct-21-16 | Initiated | Stifel | Buy |
| Sep-26-16 | Initiated | Guggenheim | Buy |
| Apr-14-16 | Reiterated | Jefferies | Buy |
| Oct-30-15 | Resumed | Jefferies | Buy |
| Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees - TipRanks
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
How Xenon Pharmaceuticals Inc. stock performs in rate cut cyclesJuly 2025 Fed Impact & Safe Swing Trade Setup Alerts - Newser
Ian Mortimer, Xenon Pharma CEO, sells $4365 in shares By Investing.com - Investing.com South Africa
Ian Mortimer, Xenon Pharma CEO, sells $4365 in shares - Investing.com
Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report? - Yahoo Finance
Xenon Pharmaceuticals to Host Webinar on Epilepsy Data and Commercialization Plans - TipRanks
Xenon (Nasdaq: XENE) sets AES 2025 webinar on azetukalner epilepsy data, commercialization - Stock Titan
JPMorgan Chase & Co. Cuts Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Loomis Sayles & Co. L P Sells 15,846 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
American Century Companies Inc. Takes Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Expands 2025 Equity Incentive Plan - TipRanks
(XENE) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Ameritas Investment Partners Inc. Acquires Shares of 7,758 Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (XENE): Evaluating Valuation as New Epilepsy and Dravet Data Draw Investor Attention - sahmcapital.com
Xenon Reports Second Quarter 2025 Financial Results & Business Update - ADVFN
Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 52-Week HighTime to Buy? - MarketBeat
Xenon Pharmaceuticals stock hits 52-week high at 44.58 USD By Investing.com - Investing.com Nigeria
Xenon Pharmaceuticals stock hits 52-week high at 44.58 USD - Investing.com
Xenon Pharmaceuticals to Present New Epilepsy Research at AES 2025 - TipRanks
Xenon Pharmaceuticals to Present New Data on Azetukalner and Epilepsy at American Epilepsy Society Annual Meeting 2025 - Quiver Quantitative
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025 - Caledonian Record
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High? - sharewise.com
FY2025 Earnings Estimate for XENE Issued By Chardan Capital - Defense World
Is Xenon Pharmaceuticals Inc. stock a dividend growth opportunityQuarterly Profit Report & Daily Profit Focused Screening - newser.com
Envestnet Asset Management Inc. Decreases Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - Defense World
How Xenon Pharmaceuticals Inc. stock performs during Fed tightening cyclesQuarterly Performance Summary & AI Powered Buy and Sell Recommendations - newser.com
Why Xenon Pharmaceuticals Inc. stock is recommended by analystsPortfolio Profit Report & Long-Term Growth Plans - newser.com
Why Xenon Pharmaceuticals Inc. stock could outperform in 2025Trend Reversal & AI Enhanced Execution Alerts - newser.com
Short interest data insights for Xenon Pharmaceuticals Inc.Weekly Profit Summary & Real-Time Buy Signal Alerts - newser.com
Can Xenon Pharmaceuticals Inc. stock deliver sustainable ROEInsider Selling & AI Forecasted Stock Moves - newser.com
Technical signs of recovery in Xenon Pharmaceuticals Inc.Weekly Volume Report & Target Return Focused Picks - newser.com
Bank of New York Mellon Corp Raises Stock Position in Xenon Pharmaceuticals Inc. $XENE - Defense World
Xenon Pharmaceuticals at Jefferies London: Advancing Epilepsy and Pain Treatments - Investing.com Canada
Xenon Pharmaceuticals (NASDAQ:XENE) Given New $60.00 Price Target at JPMorgan Chase & Co. - Defense World
XENE: JP Morgan Raises Price Target to $60, Maintains Overweight Rating | XENE Stock News - GuruFocus
Using Ichimoku Cloud for Xenon Pharmaceuticals Inc. technicalsSwing Trade & Risk Managed Investment Strategies - newser.com
How strong is Xenon Pharmaceuticals Inc. stock revenue growthWeekly Risk Summary & Short-Term Swing Trade Alerts - newser.com
Will Xenon Pharmaceuticals Inc. stock continue dividend increasesQuarterly Portfolio Review & Daily Profit Focused Screening - newser.com
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):